The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2011Just in Time Pre-clinical Resource for Evaluating Symptoms & Side Effects and/or Dyskinesia Treatments
Objective/Rationale:
There is a clear need for the development of novel treatments to better manage the symptoms of Parkinson’s disease. While current treatments address some of the motor symptoms of... -
MJFF Research Grant, 2011Generation of Synthetic Alpha-synuclein for the PD Research Community
Objective/Rationale:
Despite increasing evidence linking specific modifications to alpha-synuclein (alpha-syn), alpha-synuclein aggregation, and Lewy body (LB) formation, little is still known... -
LRRK2 Target Engagement Ligand, 2011Discovery of LRRK2 Target Engagement Ligands to be Used in Imaging Studies
Objective/Rationale:
LRRK2 is an emerging target for discovery of a neuroprotective agent for treatment of PD. Multiple mutations within the LRRK2 gene are associated with PD and many of these have... -
LRRK2 Target Engagement Ligand, 2011LRRK2 Target Engagement Ligand
Objective/Rationale:
Target engagement ligands, also known as imaging agents, are useful tools in the development of drugs and this project seeks to develop such a tool for Leucine Rich Repeat Kinase... -
Rapid Response Innovation Awards, 2011Regulated GDNF Gene Therapy: a Novel Regulatory System Based on Protein Degradation
Objective/Rationale:
Gene therapy may offer effective treatments to patients. Delivering genes to cells in the body has the potential of letting the patient’s cells treat themselves. In the case of... -
MJFF Research Grant, 2011Global Estimates for the Role of LRRK2 Variation in Parkinson's Disease Susceptibility
Promising Outcomes of Original Grant:
Our original goal was to resolve the role of known LRRK2 coding variants in susceptibility to Parkinson’s disease. Our studies have nominated risk factors for...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.